SCHEMBL3584557

SCHEMBL3584557

CN(C1CCCCC1)C1Cc2c(N)cccc2NC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 4/20 0.37
CRBN Q96SW2 4/20 0.37
PABPC1 P11940 1/20 0.36
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
BRD4 O60885 3/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TNF P01375 1/20 0.32
IL1B P01584 1/20 0.32
IKZF1 Q13422 1/20 0.32
IKZF3 Q9UKT9 1/20 0.32
GAA P10253 2/20 0.32
MAPT P10636 1/20 0.32
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584555 0.86 DDB1 (0.36) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL3593980 0.83 HTR5A (0.35) DDB1CRBNBRD4TNFIL1B
SCHEMBL3597335 0.80 CRBN (0.37) DDB1CRBNPABPC1MEN1KMT2A
SCHEMBL3595541 0.76 HSP90AA1 (0.35) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL3598950 0.76 ALDH1A1 (0.34) DDB1CRBNKDM4EALDH1A1BRD4
SCHEMBL3597785 0.75 PDE3B (0.36) DDB1CRBNALDH1A1GAAMAPT
SCHEMBL3589697 0.75 CA9 (0.40) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL3592386 0.75 TRPV1 (0.38) DDB1CRBNKDM4EALDH1A1MAPT
SCHEMBL3590436 0.73 TRPV1 (0.40) DDB1CRBNKDM4EALDH1A1
SCHEMBL27746212 0.70 PARP1 (0.37) DDB1CRBNKDM4EALDH1A1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 DDB1 1855/4885CRBN 762/4885PABPC1 4846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.